The Case for Conservative Management of Early HIV Disease

作者：William J. Burman · 发表于：JAMA · 年份：1998 · DOI：10.1001/jama.280.1.93 · 被引用次数：28 · 研究领域：HIV Research and Treatment、HIV/AIDS drug development and treatment、HIV/AIDS Research and Interventions

viral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116. 13. Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis. 1998;177:898-904. 14. Currier JS, Williams PL, Grimes JM, Squires KS, Fischl MA, Hammer SM. Incidence rates and risk factors for opportunistic infections in a phase III trial comparing indinavir + ZDV to ZDV + 3TC. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections; February 1-5, 1998; Chicago, Ill. 15. Harrer T, Harrer E, Kalams SA, et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses. 1996;12:585-592. 16. Harrer T, Harrer E, Kalams SA, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection: breadth and specificity of the response and relation to in vivo viral quasispecies in a person with prolonged infection and low viral load. J Immunol. 1996;156:2616-2623. 17. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997;278: 1447-1450. 18. Spruance SL, Pavia AT, Mellors JW, et al, for the Bristol-Myers Squibb Stavudine/019 Study Group. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HI...